Advagene obtained the technology authorization from National Institutes of Health(NIH), to use influenza virus particle platform to develop SARS-Cov-2 antigen. This antigen technology will be used for the development of the second-generation nasal spray COVID-19 vaccine, which can induce both serum and mucosal antibodies after vaccination. And it provides injection-free vaccination and additional mucosal protection.